These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15884041)

  • 1. Genetic testing in Parkinson's disease.
    McInerney-Leo A
    Mov Disord; 2005 Jul; 20(7):908-9. PubMed ID: 15884041
    [No Abstract]   [Full Text] [Related]  

  • 2. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
    Kay DM; Kramer P; Higgins D; Zabetian CP; Payami H
    Mov Disord; 2005 Aug; 20(8):1077-8. PubMed ID: 16001413
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 5. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
    Melamed E
    Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
    [No Abstract]   [Full Text] [Related]  

  • 6. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
    Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
    Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
    Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
    Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 mutations in Basque patients with Parkinson's disease.
    Zarranz JJ; Gómez-Esteban JC
    Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
    Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
    Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
    Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
    Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
    Lesage S; Ibanez P; Lohmann E; Pollak P; Tison F; Tazir M; Leutenegger AL; Guimaraes J; Bonnet AM; Agid Y; Dürr A; Brice A;
    Ann Neurol; 2005 Nov; 58(5):784-7. PubMed ID: 16240353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
    Goldwurm S; Tunesi S; Tesei S; Zini M; Sironi F; Primignani P; Magnani C; Pezzoli G
    Mov Disord; 2011 Sep; 26(11):2144-5. PubMed ID: 21714003
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
    Nichols WC; Pankratz N; Hernandez D; Paisán-Ruíz C; Jain S; Halter CA; Michaels VE; Reed T; Rudolph A; Shults CW; Singleton A; Foroud T;
    Lancet; 2005 Jan 29-Feb 4; 365(9457):410-2. PubMed ID: 15680455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
    Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
    Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
    Shanker V; Groves M; Heiman G; Palmese C; Saunders-Pullman R; Ozelius L; Raymond D; Bressman S
    Mov Disord; 2011 Aug; 26(10):1875-80. PubMed ID: 21611978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2: both a cause and a risk factor for Parkinson disease?
    Foroud T
    Neurology; 2005 Sep; 65(5):664-5. PubMed ID: 16157895
    [No Abstract]   [Full Text] [Related]  

  • 18. Gene mutation detected in Parkinson's disease.
    Passey S
    Lancet Neurol; 2005 Mar; 4(3):142-3. PubMed ID: 15744939
    [No Abstract]   [Full Text] [Related]  

  • 19. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.
    Tan EK; Shen H; Tan LC; Farrer M; Yew K; Chua E; Jamora RD; Puvan K; Puong KY; Zhao Y; Pavanni R; Wong MC; Yih Y; Skipper L; Liu JJ
    Neurosci Lett; 2005 Aug; 384(3):327-9. PubMed ID: 15955629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
    Munhoz RP; Wakutani Y; Marras C; Teive HA; Raskin S; Werneck LC; Moreno D; Sato C; Lang AE; Rogaeva E
    Mov Disord; 2008 Jan; 23(2):290-4. PubMed ID: 17999435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.